Antiangiogenic therapies in epithelial ovarian cancer

Cancer Control

Volumn 18, Issue 1, 2011, Pages 31-43

  Teoh, Deanna G K ^a   Secord, Angeles Alvarez ^a,b  

^a DUKE CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; AMG 386; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; COMBRETASTATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VATALANIB;

ANOREXIA; ANTIANGIOGENIC THERAPY; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CANCER PAIN; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOKALEMIA; INTESTINE PERFORATION; KIDNEY CARCINOMA; LEUKOPENIA; LOW DRUG DOSE; LUNG EMBOLISM; LYMPHOCYTOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; OVARY CANCER; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEINURIA; PULMONARY HYPERTENSION; QT PROLONGATION; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR VASCULARIZATION; ULCER; VOMITING;

EID: 78651481637     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481101800105     Document Type: Article

References (79)

1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82(1):4-6.
2. Abulafia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol. 1997;177(3): 541-547.
3. Alvarez AA, Krigman HR, Whitaker RS, et al. The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res. 1999;5(3):587-591.
4. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol. 1995;147(1):9-19.
5. Goodheart MJ, Vasef MA, Sood AK, et al. Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol Oncol. 2002; 86(1):85-90.
6. Stone PJ, Goodheart MJ, Rose SL, et al. The influence of microvessel density on ovarian carcinogenesis. Gynecol Oncol. 2003;90(3):566-571.
7. Abulafia O, Triest WE, Sherer DM. Angiogenesis in primary and metastatic epithelial ovarian carcinoma. Am J Obstet Gynecol. 1997;177(3): 541-547.
8. O'Toole SA, Sheppard BL, Laios A, et al. Potential predictors of chemotherapy response in ovarian cancer--how do we define chemosensitivity? Gynecol Oncol. 2007;104(2):345-351.
9. Palmer JE, Sant Cassia LJ, Irwin CJ, et al. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. Int J Gynecol Pathol. 2007;26(4):395-403.
10. Goodheart MJ, Ritchie JM, Rose SL, et al. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 2005;11(10):3733-3742.
11. Raspollini MR, Castiglione F, Garbini F, et al. Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol. 2005;13(2):135-142.
12. Raspollini MR, Amunni G, Villanucci A, et al. COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates. Oncol Rep. 2004; 11(2):309-313.
13. Yabushita H, Noguchi M, Obayashi Y, et al. Angiostatin expression in ovarian cancer. Oncol Rep. 2003;10(5):1225-1230.
14. Gasparini G, Bonoldi E, Viale G, et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer. 1996;69(3): 205-211.
15. Schoell WM, Pieber D, Reich O, et al. Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis. Cancer. 1997;80(12):2257-2262.
16. Raspollini MR, Amunni G, Villanucci A, et al. Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int J Gynecol Cancer. 2004;14(5):815-823.
17. Raspollini MR, Amunni G, Villanucci A, et al. Microvessel density in ovarian carcinoma: computer image analysis in patients with shorter and longer survival. Int J Gynecol Cancer. 2005;15(5):844-849.
18. Obermair A, Wasicky R, Kaider A, et al. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett. 1999;138(1-2): 175-182.
19. Heimburg S, Oehler MK, Papadopoulos T, et al. Prognostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res. 1999;19(4A):2527-2529.
20. Taskiran C, Erdem O, Onan A, et al. The prognostic value of endoglin (CD105) expression in ovarian carcinoma. Int J Gynecol Cancer. 2006;16(5): 1789-1793.
21. Gadducci A, Viacava P, Cosio S, et al. Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res. 2003;23(1B):549-556.
22. Gadducci A, Ferrero A, Cosio S, et al. Intratumoral microvessel density in advanced epithelial ovarian cancer and its use as a prognostic variable. Anticancer Res. 2006;26(5B):3925-3932.
23. Chan JK, Loizzi V, Magistris A, et al. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer. Clin Cancer Res. 2004;10(24):8538-8543.
24. Hollingsworth HC, Kohn EC, Steinberg SM, et al. Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol. 1995;147(1):33-41.
25. Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a Gynecologic Oncology Group study. Gynecol Oncol. 2009; 112(3):469-474.
26. Henriksen R, Gobl A, Wilander E, et al. Expression and prognostic significance of TGF-beta isotypes, latent TGF-beta 1 binding protein, TGFbeta type I and type II receptors, and endoglin in normal ovary and ovarian neoplasms. Lab Invest. 1995;73:213-220.
27. Martin L, Schilder R. Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol. 2007;25(20):2894-2901.
28. Nagy JA, Dvorak AM, Dvorak HF. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007;2:251-275.
29. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1(10):1024-1028.
30. Ramakrishnan S, Subramanian IV, Yokoyama Y, et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005;8(2):169-182.
31. Zhang L, Yang N, Garcia JR, et al. Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002;161(6):2295-2309.
32. Kassim SK, El-Salahy EM, Fayed ST, et al. Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clin Biochem. 2004;37(5):363-369.
33. Cooper BC, Ritchie JM, Broghammer CL, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193-3197.
34. Li L, Wang L, Zhang W, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Res. 2004;24(3b):1973-1979.
35. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer. 1997;80(1):98-106.
36. Hefler LA, Zeillinger R, Grimm C, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512-517.
37. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25(33):5165-5171.
38. Cannistra SA, Matulonis UA, Penson RT, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180-5186. Erratum in: J Clin Oncol. 2008;26(10):1773.
39. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005;69(suppl 3):25-33.
40. Wright JD, Secord AA, Numnum TM, et al. A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancer. Int J Gynecol Cancer. 2008;18(3):400-406.
41. Sfakianos GP, Numnum TM, Halverson CB, et al. The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: a retrospective cohort study. Gynecol Oncol. 2009;114(3):424-426.
42. Cohn DE, Valmadre S, Resnick KE, et al. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol Oncol. 2006;102(2):134-139.
43. Wright JD, Hagemann A, Rader JS, et al. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis. Cancer. 2006;107(1):83-89.
44. Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol. 2008;26(1):76-82.
45. Rose PG, Drake R, Braly PS, et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol, 2009 ASCO Ann Meet Proc (Post-Meet Ed). 2009;27(15S May 20 suppl):5546. Abstract.
46. Micha JP, Goldstein BH, Rettenmaier MA, et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advancedstage epithelial ovarian, peritoneal, and fallopian tube cancer. Int J Gynecol Cancer. 2007;17(4):771-776.
47. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol. 2010;28(18s):LBA1. Abstract.
48. Han ES, Burger R, Darcy KM et al. Relationship between angiogenic markers and clinicopathologic factors/outcome in GOG-170D, a phase II trial of bevacizumab (Bev) in recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal cancer (PPC). J Clin Oncol, 2008 ASCO Ann Meet Proc (Post-Meet Ed). 2008;26(15S May 20 suppl):5577. Abstract.
49. Smerdel MP, Steffensen KD, Waldstrøm M, et al. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol. 2010;118(2):167-171.
50. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-11398.
51. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factortrap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9(15):5721-5728.
52. Tew WP, Colombo N, Ray-Coquard I et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol, 2007 ASCO Ann Meet Proc (Post-Meet Ed). 2007;25(18S June 20 suppl): 5508. Abstract.
53. Sanofi-Aventis and Regeneron update aflibercept (VEGF trap) clinical development program in oncology. http://www.medicalnewstoday.com/ articles/108335.php. Accessed August 3, 2010.
54. Colombo N, Mangili G, Mammoliti S et al. Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study. J Clin Oncol, 2008 ASCO Ann Meet Proc (Post-Meet Ed). 2008;26(15S May 20 suppl):14598. Abstract.
55. Coleman RL, Kamat A, Iyer R et al. Phase I and pharmacokinetic study of the novel VEGF-directed fusion protein, aflibercept, in combination with docetaxel in women with recurrent ovarian, fallopian tube, and primary peritoneal cancer. J Clin Oncol, 2009 ASCO Ann Meet Proc (Post-Meet Ed). 2009;27(15S May 20 suppl):5549. Abstract.
56. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601-5606.
57. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol. 2005;16(10):1688-1694.
58. Matei D, Sill MW, DeGeest K, et al. Phase II trial of sorafenib in persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC): A Gynecologic Oncology Group (GOG) study. J Clin Oncol, 2008 ASCO Ann Meet Proc (Post-Meet Ed). 2008;26(15S May 20 suppl):5537. Abstract.
59. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res. 2006;12(1):144-151.
60. Buckstein R, Meyer RM, Seymour L, et al. Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185. Curr Oncol. 2007;14(4):154-161.
61. National Cancer Institute Clinical Trials. http://www.cancer.gov/ search/ResultsClinicalTrials.aspx?protocolsearchid=7126361. Accessed August 3, 2010.
62. Friedlander M, Hancock KC, Benigno B, et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. J Clin Oncol, 2007 ASCO Ann Meet Proc (Post-Meet Ed). 2007;25(18S June 20 suppl):5561. Abstract.
63. Xu L, Yoneda J, Herrera C, et al. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol. 2000;16(3):445-454.
64. Schroder W, Witteveen E, Abadie S et al. A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to IV epithelial ovarian cancer. J Clin Oncol, 2007 ASCO Ann Meet Proc (Post-Meet Ed). 2005;23(16S June 1 suppl):5042. Abstract.
65. Juretzka MM Aghajanian C Hensley ML, et al. Phase I trial of PTK787/ZK222584 (PTK/ZK) in combination with carboplatin (C) and paclitaxel (T) in platinum-sensitive recurrent epithelial ovarian (EOC), fallopian tube (FT), or primary peritoneal (PPC) cancers. J Clin Oncol, 2007 ASCO Ann Meet Proc (Post-Meet Ed). 2007;25(18S June 20 suppl):5564. Abstract.
66. Lin YG, Han LY, Kamat AA, et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer. 2007;109(2):332-340.
67. Landen CN Jr, Lu C, Han LY, et al. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst. 2006;98(21):1558-1570.
68. Lee JW, Han HD, Shahzad MM, et al. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009;101(17):1193-1205.
69. Karlan BY, Oza AM, Hansen VL et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly pa clitaxel in patients (pts) with recurrent ovarian carcinoma. J Clin Oncol. 2010;28(15s):5000. Abstract.
70. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008;28(4B):2027-2031.
71. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62(12):3408-3416.
72. Hua J, Sheng Y, Pinney KG, et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res. 2003;23(2B):1433-1440.
73. Malcontenti-Wilson C, Chan L, Nikfarjam M, et al. Vascular targeting agent Oxi4503 inhibits tumor growth in a colorectal liver metastases model. J Gastroenterol Hepatol. 2008;23(7 Pt 2):e96-e104.
74. Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res. 2006;12(13):4090-4094.
75. Salmon HW, Mladinich C, Siemann DW. Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting technique. Eur J Cancer. 2006;42(17):3073-3078.
76. LoRusso PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs. 2008;26(2):159-167.
77. Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007;67(19):9337-9345.
78. Tolcher AW, Forero L, Celio P et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. Proc Annu Meet Am Soc Clin Oncol. 2003;22:834. Abstract.
79. Hande KR, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res. 2006;12(9):2834-2840.